Synergistic Anticancer Activity of Fucoidan from Lessonia trabeculata Combined with Chemotherapeutic Agents in 4T1 Breast Spheroids Article Swipe
Rosa María Condori Macuri
,
Libertad Alzamora-Gonzales
,
Erasmo Honorio Colona-Vallejos
,
Raisa Teresa Cruz Riquelme
,
Laura Inés Pecho Chávez
,
Jherson Oscar Cisneros Gutierrez
,
Victor Alonso Montejo Anlas
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/md23120451
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/md23120451
Triple-negative breast cancer (TNBC) is known for being aggressive and potentially resistant to chemotherapy. This means that new ways to improve cancer treatments are a priority. So, the anticancer effect of binary combinations of fucoidan (FuLt) and the chemotherapeutic agents doxorubicin, paclitaxel, and 5-fluorouracil was evaluated. The Chou-Talalay combination index method was used to do this. This method allows the assessment of interactions between products by determining synergism, additive effect and antagonism with combination index <1, =1 and >1, respectively. Synergistic indices (SIs) were selected and applied to 4T1 homotypic spheroids. Oxidative stress caused by SIs was determined after 72 h by measuring the production of ROS and NO in both homotypic and heterotypic spheroids. Three SIs with an inhibitory effect of at least ≥ 0.50 and a dose reduction index > 1 were selected. Considering the experimental and simulated SI, twelve, nineteen, and seven SIs were found for FuLt with doxorubicin, paclitaxel, and 5-fluorouracil, respectively. The highest levels of ROS and NO occurred at 12 and 72 h, respectively, in homotypic and heterotypic spheroids, indicating an immunomodulatory effect in heterotypic spheroids. These results suggest that the synergistic combination of FuLt with chemotherapeutic agents improves drug efficacy and modulates redox dynamics in 4T1 spheroids. Furthermore, FuLt alone exhibits cytotoxic properties.
Related Topics
Concepts
Fucoidan
Chemistry
Antagonism
Pharmacology
Oxidative stress
Cancer research
Drug
Cancer cell
Inhibitory postsynaptic potential
Breast cancer
Cytotoxic T cell
Cytotoxicity
Spheroid
Chemotherapeutic drugs
Cancer
Doxorubicin
Therapeutic index
Combination therapy
MCF-7
Human breast
Anticancer drug
Cell culture
Paclitaxel
In vitro
Apoptosis
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/md23120451
- https://www.mdpi.com/1660-3397/23/12/451/pdf
- OA Status
- gold
- References
- 57
- OpenAlex ID
- https://openalex.org/W7106646634
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W7106646634Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/md23120451Digital Object Identifier
- Title
-
Synergistic Anticancer Activity of Fucoidan from Lessonia trabeculata Combined with Chemotherapeutic Agents in 4T1 Breast SpheroidsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-11-26Full publication date if available
- Authors
-
Rosa María Condori Macuri, Libertad Alzamora-Gonzales, Erasmo Honorio Colona-Vallejos, Raisa Teresa Cruz Riquelme, Laura Inés Pecho Chávez, Jherson Oscar Cisneros Gutierrez, Victor Alonso Montejo AnlasList of authors in order
- Landing page
-
https://doi.org/10.3390/md23120451Publisher landing page
- PDF URL
-
https://www.mdpi.com/1660-3397/23/12/451/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/1660-3397/23/12/451/pdfDirect OA link when available
- Concepts
-
Fucoidan, Chemistry, Antagonism, Pharmacology, Oxidative stress, Cancer research, Drug, Cancer cell, Inhibitory postsynaptic potential, Breast cancer, Cytotoxic T cell, Cytotoxicity, Spheroid, Chemotherapeutic drugs, Cancer, Doxorubicin, Therapeutic index, Combination therapy, MCF-7, Human breast, Anticancer drug, Cell culture, Paclitaxel, In vitro, ApoptosisTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
57Number of works referenced by this work
Full payload
| id | https://openalex.org/W7106646634 |
|---|---|
| doi | https://doi.org/10.3390/md23120451 |
| ids.doi | https://doi.org/10.3390/md23120451 |
| ids.openalex | https://openalex.org/W7106646634 |
| fwci | 0.0 |
| type | article |
| title | Synergistic Anticancer Activity of Fucoidan from Lessonia trabeculata Combined with Chemotherapeutic Agents in 4T1 Breast Spheroids |
| biblio.issue | 12 |
| biblio.volume | 23 |
| biblio.last_page | 451 |
| biblio.first_page | 451 |
| is_xpac | False |
| apc_list.value | 2500 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2707 |
| apc_paid.value | 2500 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2707 |
| concepts[0].id | https://openalex.org/C2775909754 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8696868419647217 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1144687 |
| concepts[0].display_name | Fucoidan |
| concepts[1].id | https://openalex.org/C185592680 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6766284704208374 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[1].display_name | Chemistry |
| concepts[2].id | https://openalex.org/C2777383412 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6012373566627502 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q4770891 |
| concepts[2].display_name | Antagonism |
| concepts[3].id | https://openalex.org/C98274493 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5835569500923157 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[3].display_name | Pharmacology |
| concepts[4].id | https://openalex.org/C2776151105 |
| concepts[4].level | 2 |
| concepts[4].score | 0.551009476184845 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q898814 |
| concepts[4].display_name | Oxidative stress |
| concepts[5].id | https://openalex.org/C502942594 |
| concepts[5].level | 1 |
| concepts[5].score | 0.47822999954223633 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[5].display_name | Cancer research |
| concepts[6].id | https://openalex.org/C2780035454 |
| concepts[6].level | 2 |
| concepts[6].score | 0.41058042645454407 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[6].display_name | Drug |
| concepts[7].id | https://openalex.org/C96232424 |
| concepts[7].level | 3 |
| concepts[7].score | 0.3892900049686432 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q4118072 |
| concepts[7].display_name | Cancer cell |
| concepts[8].id | https://openalex.org/C17077164 |
| concepts[8].level | 2 |
| concepts[8].score | 0.3840439021587372 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1185869 |
| concepts[8].display_name | Inhibitory postsynaptic potential |
| concepts[9].id | https://openalex.org/C530470458 |
| concepts[9].level | 3 |
| concepts[9].score | 0.3706199824810028 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[9].display_name | Breast cancer |
| concepts[10].id | https://openalex.org/C154317977 |
| concepts[10].level | 3 |
| concepts[10].score | 0.3702157139778137 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q376266 |
| concepts[10].display_name | Cytotoxic T cell |
| concepts[11].id | https://openalex.org/C109316439 |
| concepts[11].level | 3 |
| concepts[11].score | 0.3670334815979004 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q246181 |
| concepts[11].display_name | Cytotoxicity |
| concepts[12].id | https://openalex.org/C175369904 |
| concepts[12].level | 3 |
| concepts[12].score | 0.3564550280570984 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q208395 |
| concepts[12].display_name | Spheroid |
| concepts[13].id | https://openalex.org/C3020391286 |
| concepts[13].level | 3 |
| concepts[13].score | 0.3467884063720703 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[13].display_name | Chemotherapeutic drugs |
| concepts[14].id | https://openalex.org/C121608353 |
| concepts[14].level | 2 |
| concepts[14].score | 0.3401711881160736 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[14].display_name | Cancer |
| concepts[15].id | https://openalex.org/C2781303535 |
| concepts[15].level | 3 |
| concepts[15].score | 0.32568246126174927 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q18936 |
| concepts[15].display_name | Doxorubicin |
| concepts[16].id | https://openalex.org/C19831878 |
| concepts[16].level | 3 |
| concepts[16].score | 0.3003082275390625 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q659446 |
| concepts[16].display_name | Therapeutic index |
| concepts[17].id | https://openalex.org/C2776999253 |
| concepts[17].level | 2 |
| concepts[17].score | 0.286138653755188 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q1304270 |
| concepts[17].display_name | Combination therapy |
| concepts[18].id | https://openalex.org/C109541995 |
| concepts[18].level | 5 |
| concepts[18].score | 0.2838573455810547 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q1881253 |
| concepts[18].display_name | MCF-7 |
| concepts[19].id | https://openalex.org/C2994423619 |
| concepts[19].level | 4 |
| concepts[19].score | 0.2814115285873413 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q9103 |
| concepts[19].display_name | Human breast |
| concepts[20].id | https://openalex.org/C3018146709 |
| concepts[20].level | 3 |
| concepts[20].score | 0.27798008918762207 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[20].display_name | Anticancer drug |
| concepts[21].id | https://openalex.org/C81885089 |
| concepts[21].level | 2 |
| concepts[21].score | 0.27777543663978577 |
| concepts[21].wikidata | https://www.wikidata.org/wiki/Q189082 |
| concepts[21].display_name | Cell culture |
| concepts[22].id | https://openalex.org/C2777292972 |
| concepts[22].level | 3 |
| concepts[22].score | 0.2711125314235687 |
| concepts[22].wikidata | https://www.wikidata.org/wiki/Q423762 |
| concepts[22].display_name | Paclitaxel |
| concepts[23].id | https://openalex.org/C202751555 |
| concepts[23].level | 2 |
| concepts[23].score | 0.2698454260826111 |
| concepts[23].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[23].display_name | In vitro |
| concepts[24].id | https://openalex.org/C190283241 |
| concepts[24].level | 2 |
| concepts[24].score | 0.26142725348472595 |
| concepts[24].wikidata | https://www.wikidata.org/wiki/Q14599311 |
| concepts[24].display_name | Apoptosis |
| keywords[0].id | https://openalex.org/keywords/fucoidan |
| keywords[0].score | 0.8696868419647217 |
| keywords[0].display_name | Fucoidan |
| keywords[1].id | https://openalex.org/keywords/antagonism |
| keywords[1].score | 0.6012373566627502 |
| keywords[1].display_name | Antagonism |
| keywords[2].id | https://openalex.org/keywords/oxidative-stress |
| keywords[2].score | 0.551009476184845 |
| keywords[2].display_name | Oxidative stress |
| keywords[3].id | https://openalex.org/keywords/drug |
| keywords[3].score | 0.41058042645454407 |
| keywords[3].display_name | Drug |
| keywords[4].id | https://openalex.org/keywords/cancer-cell |
| keywords[4].score | 0.3892900049686432 |
| keywords[4].display_name | Cancer cell |
| keywords[5].id | https://openalex.org/keywords/inhibitory-postsynaptic-potential |
| keywords[5].score | 0.3840439021587372 |
| keywords[5].display_name | Inhibitory postsynaptic potential |
| keywords[6].id | https://openalex.org/keywords/breast-cancer |
| keywords[6].score | 0.3706199824810028 |
| keywords[6].display_name | Breast cancer |
| keywords[7].id | https://openalex.org/keywords/cytotoxic-t-cell |
| keywords[7].score | 0.3702157139778137 |
| keywords[7].display_name | Cytotoxic T cell |
| keywords[8].id | https://openalex.org/keywords/cytotoxicity |
| keywords[8].score | 0.3670334815979004 |
| keywords[8].display_name | Cytotoxicity |
| language | en |
| locations[0].id | doi:10.3390/md23120451 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S146563757 |
| locations[0].source.issn | 1660-3397 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1660-3397 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Marine Drugs |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/1660-3397/23/12/451/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Marine Drugs |
| locations[0].landing_page_url | https://doi.org/10.3390/md23120451 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A4320664203 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2177-3462 |
| authorships[0].author.display_name | Rosa María Condori Macuri |
| authorships[0].countries | PE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I192513696 |
| authorships[0].affiliations[0].raw_affiliation_string | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[0].institutions[0].id | https://openalex.org/I192513696 |
| authorships[0].institutions[0].ror | https://ror.org/https://ror.org/006vs7897 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I192513696 |
| authorships[0].institutions[0].country_code | PE |
| authorships[0].institutions[0].display_name | National University of San Marcos |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Rosa María Condori Macuri |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[1].author.id | https://openalex.org/A2183191527 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7425-7453 |
| authorships[1].author.display_name | Libertad Alzamora-Gonzales |
| authorships[1].countries | PE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I192513696 |
| authorships[1].affiliations[0].raw_affiliation_string | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[1].institutions[0].id | https://openalex.org/I192513696 |
| authorships[1].institutions[0].ror | https://ror.org/https://ror.org/006vs7897 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I192513696 |
| authorships[1].institutions[0].country_code | PE |
| authorships[1].institutions[0].display_name | National University of San Marcos |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Libertad Alzamora-Gonzales |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[2].author.id | |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Erasmo Honorio Colona-Vallejos |
| authorships[2].countries | PE |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I192513696 |
| authorships[2].affiliations[0].raw_affiliation_string | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[2].institutions[0].id | https://openalex.org/I192513696 |
| authorships[2].institutions[0].ror | https://ror.org/https://ror.org/006vs7897 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I192513696 |
| authorships[2].institutions[0].country_code | PE |
| authorships[2].institutions[0].display_name | National University of San Marcos |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Erasmo Honorio Colona-Vallejos |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[3].author.id | |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Raisa Teresa Cruz Riquelme |
| authorships[3].countries | PE |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I192513696 |
| authorships[3].affiliations[0].raw_affiliation_string | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[3].institutions[0].id | https://openalex.org/I192513696 |
| authorships[3].institutions[0].ror | https://ror.org/https://ror.org/006vs7897 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I192513696 |
| authorships[3].institutions[0].country_code | PE |
| authorships[3].institutions[0].display_name | National University of San Marcos |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Raisa Teresa Cruz Riquelme |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[4].author.id | |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Laura Inés Pecho Chávez |
| authorships[4].countries | PE |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I192513696 |
| authorships[4].affiliations[0].raw_affiliation_string | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[4].institutions[0].id | https://openalex.org/I192513696 |
| authorships[4].institutions[0].ror | https://ror.org/https://ror.org/006vs7897 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I192513696 |
| authorships[4].institutions[0].country_code | PE |
| authorships[4].institutions[0].display_name | National University of San Marcos |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Laura Inés Pecho Chávez |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[5].author.id | |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Jherson Oscar Cisneros Gutierrez |
| authorships[5].countries | PE |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I192513696 |
| authorships[5].affiliations[0].raw_affiliation_string | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[5].institutions[0].id | https://openalex.org/I192513696 |
| authorships[5].institutions[0].ror | https://ror.org/https://ror.org/006vs7897 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I192513696 |
| authorships[5].institutions[0].country_code | PE |
| authorships[5].institutions[0].display_name | National University of San Marcos |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Jherson Oscar Cisneros Gutierrez |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[6].author.id | |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Victor Alonso Montejo Anlas |
| authorships[6].countries | PE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I192513696 |
| authorships[6].affiliations[0].raw_affiliation_string | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| authorships[6].institutions[0].id | https://openalex.org/I192513696 |
| authorships[6].institutions[0].ror | https://ror.org/https://ror.org/006vs7897 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I192513696 |
| authorships[6].institutions[0].country_code | PE |
| authorships[6].institutions[0].display_name | National University of San Marcos |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Victor Alonso Montejo Anlas |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Research Group Immunomodulators and Antitumor of Natural and Synthetic Origen, Immunology Laboratory, Universidad Nacional Mayor de San Marcos, Lima 11-0058, Peru |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/1660-3397/23/12/451/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-11-27T00:00:00 |
| display_name | Synergistic Anticancer Activity of Fucoidan from Lessonia trabeculata Combined with Chemotherapeutic Agents in 4T1 Breast Spheroids |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-28T02:08:47.144824 |
| primary_topic | |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.3390/md23120451 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S146563757 |
| best_oa_location.source.issn | 1660-3397 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1660-3397 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Marine Drugs |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/1660-3397/23/12/451/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Marine Drugs |
| best_oa_location.landing_page_url | https://doi.org/10.3390/md23120451 |
| primary_location.id | doi:10.3390/md23120451 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S146563757 |
| primary_location.source.issn | 1660-3397 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1660-3397 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Marine Drugs |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/1660-3397/23/12/451/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Marine Drugs |
| primary_location.landing_page_url | https://doi.org/10.3390/md23120451 |
| publication_date | 2025-11-26 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4379196753, https://openalex.org/W3188787409, https://openalex.org/W3155496868, https://openalex.org/W4323309345, https://openalex.org/W4311677374, https://openalex.org/W4292415327, https://openalex.org/W3105660684, https://openalex.org/W3198264011, https://openalex.org/W2932409564, https://openalex.org/W4386393293, https://openalex.org/W4388295741, https://openalex.org/W4389656326, https://openalex.org/W4391076075, https://openalex.org/W4399138491, https://openalex.org/W4401520124, https://openalex.org/W2977699141, https://openalex.org/W3174908993, https://openalex.org/W2620831678, https://openalex.org/W2889902247, https://openalex.org/W3205744120, https://openalex.org/W4410828090, https://openalex.org/W2046122149, https://openalex.org/W2096439168, https://openalex.org/W3022483688, https://openalex.org/W3190429855, https://openalex.org/W4214809366, https://openalex.org/W4320920033, https://openalex.org/W1986485320, https://openalex.org/W2018502785, https://openalex.org/W2148307677, https://openalex.org/W2103403761, https://openalex.org/W2167692237, https://openalex.org/W1988249582, https://openalex.org/W2075149491, https://openalex.org/W4296029171, https://openalex.org/W3136540301, https://openalex.org/W2947117326, https://openalex.org/W2157719288, https://openalex.org/W2059404629, https://openalex.org/W3167009875, https://openalex.org/W2014297192, https://openalex.org/W2005370671, https://openalex.org/W2129739698, https://openalex.org/W2999330425, https://openalex.org/W4224990412, https://openalex.org/W1946503577, https://openalex.org/W2942814044, https://openalex.org/W4283698994, https://openalex.org/W2028915055, https://openalex.org/W4323859231, https://openalex.org/W2104529242, https://openalex.org/W1985029004, https://openalex.org/W2118592295, https://openalex.org/W4376641385, https://openalex.org/W4280608387, https://openalex.org/W2593994335, https://openalex.org/W2114723423 |
| referenced_works_count | 57 |
| abstract_inverted_index.1 | 132 |
| abstract_inverted_index.a | 24, 127 |
| abstract_inverted_index.h | 100 |
| abstract_inverted_index.12 | 165 |
| abstract_inverted_index.72 | 99, 167 |
| abstract_inverted_index.=1 | 76 |
| abstract_inverted_index.NO | 108, 162 |
| abstract_inverted_index.an | 118, 176 |
| abstract_inverted_index.at | 122, 164 |
| abstract_inverted_index.by | 65, 94, 101 |
| abstract_inverted_index.do | 54 |
| abstract_inverted_index.h, | 168 |
| abstract_inverted_index.in | 109, 170, 179, 201 |
| abstract_inverted_index.is | 4 |
| abstract_inverted_index.of | 30, 33, 61, 105, 121, 159, 189 |
| abstract_inverted_index.to | 12, 19, 53, 87 |
| abstract_inverted_index.4T1 | 88, 202 |
| abstract_inverted_index.ROS | 106, 160 |
| abstract_inverted_index.SI, | 140 |
| abstract_inverted_index.SIs | 95, 116, 145 |
| abstract_inverted_index.So, | 26 |
| abstract_inverted_index.The | 46, 156 |
| abstract_inverted_index.and | 9, 36, 42, 70, 77, 85, 107, 112, 126, 138, 143, 153, 161, 166, 172, 197 |
| abstract_inverted_index.are | 23 |
| abstract_inverted_index.for | 6, 148 |
| abstract_inverted_index.new | 17 |
| abstract_inverted_index.the | 27, 37, 59, 103, 136, 186 |
| abstract_inverted_index.was | 44, 51, 96 |
| abstract_inverted_index.≥ | 124 |
| abstract_inverted_index.> | 131 |
| abstract_inverted_index.0.50 | 125 |
| abstract_inverted_index.FuLt | 149, 190, 205 |
| abstract_inverted_index.This | 14, 56 |
| abstract_inverted_index.both | 110 |
| abstract_inverted_index.dose | 128 |
| abstract_inverted_index.drug | 195 |
| abstract_inverted_index.that | 16, 185 |
| abstract_inverted_index.used | 52 |
| abstract_inverted_index.ways | 18 |
| abstract_inverted_index.were | 83, 133, 146 |
| abstract_inverted_index.with | 72, 117, 150, 191 |
| abstract_inverted_index.(SIs) | 82 |
| abstract_inverted_index.These | 182 |
| abstract_inverted_index.Three | 115 |
| abstract_inverted_index.after | 98 |
| abstract_inverted_index.alone | 206 |
| abstract_inverted_index.being | 7 |
| abstract_inverted_index.found | 147 |
| abstract_inverted_index.index | 49, 74, 130 |
| abstract_inverted_index.known | 5 |
| abstract_inverted_index.least | 123 |
| abstract_inverted_index.means | 15 |
| abstract_inverted_index.redox | 199 |
| abstract_inverted_index.seven | 144 |
| abstract_inverted_index.this. | 55 |
| abstract_inverted_index.>1, | 78 |
| abstract_inverted_index.<1, | 75 |
| abstract_inverted_index.(FuLt) | 35 |
| abstract_inverted_index.(TNBC) | 3 |
| abstract_inverted_index.agents | 39, 193 |
| abstract_inverted_index.allows | 58 |
| abstract_inverted_index.binary | 31 |
| abstract_inverted_index.breast | 1 |
| abstract_inverted_index.cancer | 2, 21 |
| abstract_inverted_index.caused | 93 |
| abstract_inverted_index.effect | 29, 69, 120, 178 |
| abstract_inverted_index.levels | 158 |
| abstract_inverted_index.method | 50, 57 |
| abstract_inverted_index.stress | 92 |
| abstract_inverted_index.applied | 86 |
| abstract_inverted_index.between | 63 |
| abstract_inverted_index.highest | 157 |
| abstract_inverted_index.improve | 20 |
| abstract_inverted_index.indices | 81 |
| abstract_inverted_index.results | 183 |
| abstract_inverted_index.suggest | 184 |
| abstract_inverted_index.twelve, | 141 |
| abstract_inverted_index.additive | 68 |
| abstract_inverted_index.dynamics | 200 |
| abstract_inverted_index.efficacy | 196 |
| abstract_inverted_index.exhibits | 207 |
| abstract_inverted_index.fucoidan | 34 |
| abstract_inverted_index.improves | 194 |
| abstract_inverted_index.occurred | 163 |
| abstract_inverted_index.products | 64 |
| abstract_inverted_index.selected | 84 |
| abstract_inverted_index.Oxidative | 91 |
| abstract_inverted_index.cytotoxic | 208 |
| abstract_inverted_index.homotypic | 89, 111, 171 |
| abstract_inverted_index.measuring | 102 |
| abstract_inverted_index.modulates | 198 |
| abstract_inverted_index.nineteen, | 142 |
| abstract_inverted_index.priority. | 25 |
| abstract_inverted_index.reduction | 129 |
| abstract_inverted_index.resistant | 11 |
| abstract_inverted_index.selected. | 134 |
| abstract_inverted_index.simulated | 139 |
| abstract_inverted_index.aggressive | 8 |
| abstract_inverted_index.antagonism | 71 |
| abstract_inverted_index.anticancer | 28 |
| abstract_inverted_index.assessment | 60 |
| abstract_inverted_index.determined | 97 |
| abstract_inverted_index.evaluated. | 45 |
| abstract_inverted_index.indicating | 175 |
| abstract_inverted_index.inhibitory | 119 |
| abstract_inverted_index.production | 104 |
| abstract_inverted_index.spheroids, | 174 |
| abstract_inverted_index.spheroids. | 90, 114, 181, 203 |
| abstract_inverted_index.synergism, | 67 |
| abstract_inverted_index.treatments | 22 |
| abstract_inverted_index.Considering | 135 |
| abstract_inverted_index.Synergistic | 80 |
| abstract_inverted_index.combination | 48, 73, 188 |
| abstract_inverted_index.determining | 66 |
| abstract_inverted_index.heterotypic | 113, 173, 180 |
| abstract_inverted_index.paclitaxel, | 41, 152 |
| abstract_inverted_index.potentially | 10 |
| abstract_inverted_index.properties. | 209 |
| abstract_inverted_index.synergistic | 187 |
| abstract_inverted_index.Chou-Talalay | 47 |
| abstract_inverted_index.Furthermore, | 204 |
| abstract_inverted_index.combinations | 32 |
| abstract_inverted_index.doxorubicin, | 40, 151 |
| abstract_inverted_index.experimental | 137 |
| abstract_inverted_index.interactions | 62 |
| abstract_inverted_index.chemotherapy. | 13 |
| abstract_inverted_index.respectively, | 169 |
| abstract_inverted_index.respectively. | 79, 155 |
| abstract_inverted_index.5-fluorouracil | 43 |
| abstract_inverted_index.5-fluorouracil, | 154 |
| abstract_inverted_index.Triple-negative | 0 |
| abstract_inverted_index.chemotherapeutic | 38, 192 |
| abstract_inverted_index.immunomodulatory | 177 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| citation_normalized_percentile |